Introduction {#s1}
============

Acute myelogenous leukemia (AML) is a heterogeneous group of hematologic malignancies, characterized by unregulated, clonal proliferation of abnormal myeloid progenitor cells. Despite major improvements in outcome over the past decades, it remains a life-threatening malignancy in children. Several constitutive genetic variants and acquired chromosomal abnormalities have been identified as prognostic markers in leukemia ([@B1], [@B2]). In AML in children, genetic diagnostics play an extremely important role in stratifying the risk of treatment failure. Identified genetic markers together with the response to induction treatment are the most important factors that allow selection of optimal therapy for the patient. Among the most relevant factors are chromosomal translocations and gene mutations, which recently have become crucial for risk stratification in pediatric AML ([@B3], [@B4]).

Characteristics for AML genetic changes include structural chromosomal aberrations (translocations, inversions), leading to the formation of gene fusions. The fusion genes present in leukemia cells undergo expression that cause malfunctioning of their protein products ([@B4]--[@B6]). Common genetic abnormalities in AML with high frequency and well-established favorable prognostic significance include t(8;21)(q22;q22) (*RUNX1-RUNX1T1*), inv(16) (p13;q22) (*CBFB-MYH11*), and t(15;17)(q24;q21) (*PML-RARA*). A basic diagnostic tool for detecting these changes is cytogenetic analysis using the karyotyping technique, supported by fluorescence *in situ* hybridization (FISH). However, nowadays, molecular biology methods are increasingly used to detect transcripts of specific fusion genes in patient\'s leukemia cells as an important part of the diagnostic process. Molecular techniques have found wide diagnostic application in the detection of not only the best known AML-related fusion genes but also the detection of fusion partners, for example, after the *MLL* (present *KMT2A*) gene rearrangement ([@B7]).

A variety of recurrent chromosomal rearrangements involving 11q23/*MLL* gene have been reported in adult and pediatric acute leukemias. So far, more than 135 different fusion partners of *MLL* gene have been identified in acute leukemias ([@B8]). Most common for pediatric AML are translocations t(9;11)(p21.3;q23.3) (*MLL-MLLT3*), t(10;11)(p12;q23.3) (*MLL-MLLT10*), t(11;19)(q23.3;p13.1) (*MLL-ELL*), and t(6;11)(q27;q23.3) (*MLL-AFDN*) ([@B7]--[@B9]). The prognostic impact of *MLL* rearrangement depends on detected fusion partner but is not always clearly defined. However, the presence of translocation t(10;11)(p12;q23) is usually associated with a poor prognosis ([@B3], [@B7], [@B9]).

Materials and Methods {#s2}
=====================

Since June 2015, the Polish Pediatric Leukemia/Lymphoma Study Group has applied the therapeutic protocol for pediatric AML requiring extensive diagnostics of genetic changes in leukemic cells. For all patients, conventional and molecular cytogenetics analyses were recommended---classical karyotype and FISH analyses for the most common translocation in AML: t(8; 21)(q22; q22)/*RUNX1-RUNX1T1*, inv(16)(p13; q22)/*CBFB-MYH11*, t(15;17)(q24; q21)/*PML-RARA*, and *MLL* rearrangements by break-apart FISH probes. Molecular analyses were also performed to screen for further, less common transcripts of fusion genes founded in leukemia, as well as mutation in *WT1, FLT3, NPM1, CEBPA*, and *GATA1* genes. Until November 2019, molecular genetic studies were performed in 195 children with *de novo* diagnosed AML. This represents nearly all pediatric patients with AML in Poland during this period.

One of the performed molecular analyses was genotyping for carriers of fusion gene transcripts for 28 most common chromosomal translocations with prognostic significance in leukemia by a CE-marked (approved for use in Europe) *in vitro* diagnostic test based on multiplex reverse transcription--polymerase chain reaction (RT-PCR) screening assay, HemaVision-28N RT-PCR (DNA Diagnostic A/S, Risskov, Denmark). The detailed information about 28 leukemia-causing translocations detected by HemaVision-28N is presented in [Supplement Table 1](#SM1){ref-type="supplementary-material"}. Diagnostic tests were conducted on mRNA samples isolated from mononuclear cells from bone marrow collected before the treatment. For this purpose, bone marrow samples were centrifuged in a density gradient (Histopaque-1077; Sigma-Aldrich, St. Louis, MO, USA), and the obtained bone marrow mononuclear cells were lysed in TRI Reagent Solution (Thermo Fisher Scientific Baltics, Vilnius, Lithuania). The isolation of total RNA was performed according to the manufacturer\'s instructions. Next, 2 μg of non-degraded RNA was used as a template for synthesis of cDNA in RT reaction (SuperScript™ II Reverse Transcriptase; Thermo Fisher Scientific). HemaVision RT-PCR assay used cDNA as a template for multiplex PCR amplification reactions, followed by nested PCR reactions. All PCR reactions were performed with primer mixes from the HemaVision HV01-28N kit and Multiplex PCR Master Mix (Eur~x~, Gdansk, Poland). The final PCR products were analyzed by agarose gel electrophoresis.

All children were treated according to the same therapeutic protocol---AML BFM 2012/2019. The genetic tests and individual persons\' data used in publication were obtained and processed according to written informed consent obtained from guardians of all patients in accordance with the Declaration of Helsinki. The study was approved by the Ethical Committee of the Jagiellonian University in Krakow (KBET 122.6120.17.2015, dated January 29, 2015). The data that support the findings of the study are available on request from the corresponding author.

Results {#s3}
=======

In the performed molecular genetic studies, the presence of fusion genes transcripts was revealed in 46.7% (91/195 patients) ([Figure 1](#F1){ref-type="fig"}). The fusion gene transcript for translocation t(10;11)(p12;q23) (*MLL-MLLT10*) was detected in 8.9% (17/195) of cases with surprisingly the highest frequency among all other marked chromosomal abnormalities determined in HemaVision-28N. Slightly lower frequency was observed for fusion transcripts generated by chromosomal translocation t(8;21) (q22;q22) (*RUNX1-RUNX1T1*) (8.2%; 16 patients) and t(9;11)(p22:q23) (*MLL-MLLT3*) (7.7%; 15 patients). Furthermore, other AML-characteristic transcripts related to 11q23/*MLL* rearrangements, such as t(11;19)(q23;p13.1), t(6;11)(q27;q23), and t(4;11)(q21;q23), were also found. Together, five different fusion gene transcripts for 11q23/*MLL* rearrangements were detected in 43 patients (22.1%).

![Frequency of chromosomal translocations associated with leukemia detected by molecular methods (HemaVision RT-PCR; DNA Diagnostic A/S) in 195 pediatric AML patients treated in Poland from June 2015 to November 2019.](fped-08-00278-g0001){#F1}

For 14 of 17 children with molecularly confirmed of *MLL-MLLT10* fusion transcript, the results of karyotype and FISH analysis were obtained, and a summary is shown in [Table 1](#T1){ref-type="table"}. In some cases, the karyotype result indicated other position of chromosome breaks than expected due to molecular result, especially in the case of chromosome 10 (p11, p13, p?). Pediatric karyotypes always pose a great diagnostic challenge due to achieved resolution and G-band quality. Obtained cytogenetic results (karyotype, FISH) were performed in local laboratories, and molecular verification was carried out in a reference laboratory. No correction of chromosome breakpoints assessed in the classical karyotype after molecular analysis results was performed.

###### 

Clinical and genetic characteristics of 17 children with diagnosed AML and confirmed t(10;11)(p12;q23) fusion gene transcript in the molecular genetic study.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Case no**.   **Sex**   **Age at diagnosis**       **FAB**           **% Leukemic blasts in BM**   **Treatment results**                                                                                            **Karyotype[\*](#TN1){ref-type="table-fn"}**                                                                       **FISH analysis of *MLL* rearrangements**
  -------------- --------- -------------------------- ----------------- ----------------------------- ---------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------
  1              F         \<6 months old             M5                77                            CR, HSCT                                                                                                         47,XX,der(1)t(1;10;11)(q32;p13;q23)del(1)(p22.1)?add(1)(p22.1)\                                                    Positive
                                                                                                                                                                                                                       dup(1)(q21q32,der(10)t(1;10;11)(q32;p13;q23)\                                                                      
                                                                                                                                                                                                                       ins(10;11)(p13;q23q23),der(11)t(1;10;11)(q32;p13;q23),+19                                                          

  2              F         6 months old               M5                66.6                          Death due to pulmonary embolism in early relapse treatment                                                       48,XX,+6,der(10)(p?),+19                                                                                           No data

  3              M         16 years old               M5                78.2                          CR, HSCT                                                                                                         46,XY,der(3)t(3;19),t(10;11)(p13;q23),r1(19)/47,idem,+r2                                                           No data

  4              M         17 years old               M5                85                            Death due to pulmonary leukostasis, acute liver failure and cardiopulmonary failure before achieving remission   46,XY                                                                                                              Positive\
                                                                                                                                                                                                                                                                                                                                          ish der(9)t(9;10)(p21;p12)(wcp10+),der(10)t(10;11)(p11;q23)(wcp10+,wcp11+),der(11)t(11;10;9)(p11pter-q23::10p11\
                                                                                                                                                                                                                                                                                                                                          -10p12::9p21-9pter)(wcp11+,wcp10+)\[20\]

  5              M         1 year old                 M5                77                            Death in CR in course of cytomegalovirus infection after HSCT                                                    46,XY,t(10;11)(p11.2q23)                                                                                           Positive

  6              F         1 year old                 M5                76.5                          CR, HSCT                                                                                                         50,XX,+8, +8, t(10;11)(p12;q23?),+20, +21/54-57,XX,+4,+5,+6,+8+8,t(10;11)(p12;q23\"),+12,+16,+18,+19,+20,+21;+21   Positive

  7              F         10 years old               M5                41                            CR, HSCT                                                                                                         54-56, X, t(X;10;11)(q22;p13;q23),+5,+6,+8,+8,+10, del(10)(p13),+14,+18,+19,+21,+21 \[cp19\]                       Positive

  8              M         \<1 year old               Myeloid Sarcoma   6.4                           CR, HSCT                                                                                                         No cell division                                                                                                   Positive

  9              F         3$\frac{1}{2}$ years old   M5                97                            CR, HSCT                                                                                                         46,XX,t(10;11)(p12;q23)                                                                                            Positive

  10             F         5 years old                M0                No data                       CR, HSCT                                                                                                         No data                                                                                                            No data

  11             F         7 years old                M5                98.2                          CR, HSCT                                                                                                         No data                                                                                                            No data

  12             M         6 years old                M5                69                            Early relapse                                                                                                    No data                                                                                                            No data

  13             M         12 years old               M5                88                            CR, HSCT                                                                                                         46,XY,t(10;11)(p12;q13),inv(11)(q13q23)                                                                            Positive

  14             F         7 years old                No data           No data                       No data                                                                                                          46,XX,t(10;11)(p12;q23),del(12)(p12),del(16)(q12)/46,XX                                                            Positive

  15             M         1$\frac{1}{2}$ years old   No data           No data                       No data                                                                                                          46,XY,t(10;11)(p12;q23),t(12;20)(p11.2;p13) /46,XY,t(12;20)(p11.2;p13)                                             Positive

  16             F         \<6 months old             M5                81.6                          CR, HSCT                                                                                                         46,XX                                                                                                              Positive ish der(10)ins(10;11)(p12;q13q23)(5′KMT2A+)(2) nuc ish(5′KMT2Ax3,3′KMT2Ax2)(5′KMT2A con 3′KMT2Ax2)\[184/230\]

  17             F         \<1 year old               M5                76.4                          Death due to sepsis and ischemic stroke before achieving remission                                               46,XX,t(7;10)(q11.2;p11.2)/46,XX                                                                                   No data
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*M, male; F, female; BM, bone marrow; CR, complete remission; HSCT, allogenic hematopoietic stem cell transplantation*.

*In some cases, the karyotype result indicated other position of chromosome breaks than expected due to molecular result. Obtained cytogenetic results (karyotype, FISH) were performed in local laboratories, and molecular verification was carried out in a reference laboratory. No correction of chromosome breakpoints assessed in the classical karyotype after molecular analysis results was performed*.

In four of those 14 patients, only rearrangements in chromosomes 10 and 11 were observed (cases 5, 9, 8, and 16, for whom rearrangements of *MLL* gene were confirmed only by FISH). For the next seven cases, additional chromosomal abnormalities or complex karyotype was detected (cases 1, 3, 6, 7, 13, 14, and 15; the results in detail in [Table 1](#T1){ref-type="table"}). For patient 4, the karyotyping result was normal, but in a metaphase FISH, the variant translocation with chromosomes 11, 10, and 9 was confirmed (cryptic rearrangement). Moreover, variant translocations were also observed in two other cases---patient 1: t(1;10;11) and patient 7: p t(X;10:11). It should be emphasized that in all these cases the fusion gene transcript for *MLL-MLLT10* was detected in molecular studies. For the last two children (cases 2 and 17), the presence of translocation t(10;11)(p12;q23) was not simply confirmed; however, abnormalities in chromosome 10 were indicated in both cases. Unfortunately, no data from FISH analysis were available for them. In the case of low G-band quality and resolution in the karyotype analysis for children with leukemia, such results do not exclude rearrangement of chromosomes 10 and 11 for patient 2 or cryptic variant translocation of chromosomes 7, 10, and 11 for patient 17.

The clinical characteristics of 17 presented children with diagnosed AML and molecular confirmation of *MLL-MLLT10* fusion gene transcript are presented in [Table 1](#T1){ref-type="table"}. All of the children were treated according to the AML-BFM 2012/2019−10 girls and 7 boys with median age of 3.6 years (range, 4 months to 16.2 years). In four of them, hyperleukocytosis (91--245 × 10^9^/L) was observed at diagnosis. Ten patients achieved complete remission (CR) and underwent allogenic hematopoietic stem cell transplantation (HSCT). Two patients died early before achieving remission---the first because of sepsis and ischemic stroke 1.4 months after diagnosis and the second one due to pulmonary leukostasis, acute liver failure, and cardiopulmonary failure 13 days after final diagnosis of AML. Two further patients had an early relapse; one of them died because of pulmonary embolism. One patient died in CR in course of cytomegalovirus infection 2.6 months after HSCT. Median observation time was 11.5 months (range, 0.4--49.7 months). For two patients, no follow--up data were available.

Discussion {#s4}
==========

The presence of t(10;11)(p12;q23) translocation was previously identified in pediatric AML and considered as an unfavorable prognostic factor, but it was observed rarely ([@B1], [@B3], [@B8]--[@B11]). This rearrangement is described in the latest large cohort studies as the second most common translocation detected in pediatric 11q23/*MLL*-rearranged AML, after t(9;11)(p22;q23) ([@B8]). Its occurrence is being estimated at 3% ([@B3]). Surprisingly, in our research, the fusion gene transcript resulting from t(10;11)(p12;q23) frequency (8.9%) was not only the highest in the case of all detected *MLL* rearrangements but also in relation to other common chromosomal translocation in AML, among others t(8;21)(q22;q22) (*RUNX1-RUNX1T1*)-−8.2% (16/195 patients). Similar results were presented by Stasevich et al. ([@B12]), who confirmed the presence of the t(10;11)(p12;q23) at a very high level in children treated for AML in 1 year at Minsk Oncology Center. In the mentioned article, five children with of t(10;11)(p12;q23) translocation were being described among 18 pediatric patients. Worth noting, all of five children do not have the simple reciprocal translocation; in all cases, MLL-MLLT10 fusion was created by several rearrangements. Also, in our research, in 3 of 13 children with karyotype result, variant translocation of 11q23/*MLL* was revealed \[t(1;10;11), t(11;10;9), t(X;10;11)\]. Therefore, it seems that in some cases the ambiguity and complexity of changes detected by cytogenetic analysis do not always allow for a correct and rapid assessment of the presence of rearrangement of chromosomes 10 and 11 in leukemic blasts. Hence, the molecular genetic studies seem to be a more appropriate technique to unequivocal assessment of the presence of *MLL-MLLT10* fusion transcript, especially in a case of possible missing of this chromosomal aberration during karyotyping (two children with normal karyotype reported) or when no karyotyping result is obtained.

In the presented group of 17 patients with positive molecular results for *MLL-MLLT10*, in three patients (patients 10--12 in [Table 1](#T1){ref-type="table"}), there is no cytogenetic confirmation of the results because of the lack of access to archival data. For the next two patients (patients 2 and 17), only the karyotype analysis was performed, with the results not indicating the presence of *MLL* rearrangement. For this reason, no FISH analysis was performed in these cases. However, in both these cases, chromosome breakage in 10p was observed \[48,XX,+6,der(10)(p?),+19 and 46,XX,t(7;10)(q11.2;p11.2)/46,XX\]. In the context of a positive molecular result for the *MLL-MLLT10* fusion gene transcript, the presence of more complex chromosomal rearrangements, including chromosome 11 rearrangement, may be possible in these patients (cryptic or variant translocation). This also indicates the need for obligatory FISH for *MLL* rearrangements in all AML patients.

Therefore, because of the large amount of molecular diagnostic tests performed with the HemaVision-28N RT-PCR IVD assay (for 195 children diagnosed with AML) and cytogenetic confirmation of the obtained result in the 12 presented cases, also the molecular results for this group of five patients without direct cytogenetic confirmation were considered reliable and included in the analysis.

According to the recommendations of an international expert panel, the patients with translocation t(10;11)(p12;q23) should be allocated to the high-risk group of pediatric AML treatment protocols ([@B3]). The MLL gene encodes a histone methyltransferase that positively regulates homeobox (HOX) gene expression ([@B13]). The presence of MLL-MLLT10 fusion protein observed in patients with t(10;11)(p12;q23) in leukemic blasts affects the histone methylation ability and dysregulation of HOXA and MEIS1 expression, finally leading to MLL rearrangement-dependent leukemia ([@B14]). It cannot be excluded that the presence of the *MLL-MLLT10* fusion transcript detected by molecular methods in the case of variant chromosomal rearrangements or complex karyotype does not have an equally significant negative effect on cell function. However, further research is required in this matter. To sum up, it seems that fusion gene transcript resulting from t(10;11)(p12;q23) can be relatively frequent in some populations, or its frequency may be underestimated because of the difficulty of its cytogenetic assessment. Paying attention to this fact and ensuring proper genetic diagnosis seem to be important for appropriate allocation of patients to risk groups of pediatric AML treatment protocols.

Data Availability Statement {#s5}
===========================

The datasets generated for this study are available on request to the corresponding author.

Ethics Statement {#s6}
================

The studies involving human participants were reviewed and approved by Ethical Committee of the Jagiellonian University in Krakow. Written informed consent to participate in this study was provided by the participants\' legal guardian/next of kin.

Author Contributions {#s7}
====================

TK, MCz, and WBal: study concept and design, acquisition of data, analysis and interpretation of data, drafting of the manuscript, and critical revision of the manuscript for important intellectual content. PK, BS, and ML: analysis and interpretation of data and critical revision of the manuscript for important intellectual content. KP-W: analysis and interpretation of data assistance, acquisition and accumulation of data, and critical revision of the manuscript for important intellectual content. MB-M and SS: critical revision of the manuscript for important intellectual content. BS-F, MM, JS-S, JW, AR-K, AC, KM-R, MK-R, DG, JK, LM-K, EA-D, WM, RT, TS, JP, GK, AM-M, KM, WBad, KZ, TU, IK-D, MW, and MCi: acquisition of data. All authors contributed to the article and approved the submitted version.

Conflict of Interest {#s8}
====================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The authors wish to thank the colleagues in the pediatric oncology centers from Polish Pediatric Leukemia/Lymphoma Study Group (PPLLSG) for their participation in providing the clinical data and the biological material for genetic research.

Supplementary Material {#s9}
======================

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fped.2020.00278/full#supplementary-material>

###### 

Click here for additional data file.

[^1]: Edited by: Daniele Zama, Sant\'Orsola-Malpighi Polyclinic, Italy

[^2]: Reviewed by: Yana Pikman, Dana--Farber Cancer Institute, United States; Martina Pigazzi, University of Padova, Italy

[^3]: This article was submitted to Pediatric Hematology and Hematological Malignancies, a section of the journal Frontiers in Pediatrics
